British Journal of Clinical Pharmacology, 2018 June
Meera Agar
There is strong public support for the availability of medicinal cannabis, particularly for people with palliative diagnoses, though clinical data to date has been inconclusive in key symptoms such as pain and nausea, and data from other settings such as chemotherapy‐induced nausea and vomiting not readily extrapolated. In people with refractory symptoms, the consideration of unregistered products or off‐label prescribing should be guided by the potential influences of pharmacokinetic, pharmacodynamic and drug–drug interactions, supported by an informed discussion with the patient, and regular review of net clinical benefit.
Fulltext available in British Journal of Clinical Pharmacology